Nanobiotix (LTS:0QAV) Other Current Payables: €0.61 Mil (As of Dec. 2025)


LTS:0QAV Nanobiotix SA LTS:0QAV
28 GF Score
Price €35.24
! 3 Warning Signs
View Full Analysis

What is Nanobiotix Other Current Payables?

Nanobiotix LTS:0QAV +3.89% 28 Other Current Payables is €0.61 Mil as of Dec. 2025. GuruFocus rates LTS:0QAV with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Nanobiotix's Other Current Payables for the quarter that ended in Dec. 2025 was €0.61 Mil.

Nanobiotix's quarterly Other Current Payables increased from Dec. 2024 (€0.67 Mil) to Jun. 2025 (€0.71 Mil) but then declined from Jun. 2025 (€0.71 Mil) to Dec. 2025 (€0.61 Mil).

Nanobiotix's annual Other Current Payables increased from Dec. 2023 (€0.42 Mil) to Dec. 2024 (€0.67 Mil) but then declined from Dec. 2024 (€0.67 Mil) to Dec. 2025 (€0.61 Mil).

Nanobiotix Other Current Payables Related Terms

Nanobiotix Other Current Payables Historical Data

* Premium members only.

The historical data trend for Nanobiotix's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanobiotix Other Current Payables Chart

Nanobiotix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.49 0.42 0.67 0.61

Nanobiotix Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.74 0.67 0.71 0.61
LTS:0QAV
28GF Score
Nanobiotix SA LTS:0QAV
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanobiotix Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €0.61 Mil mean?
Nanobiotix (LTS:0QAV) has a Other Current Payables of €0.61 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Nanobiotix and its competitors.
Is Nanobiotix's Other Current Payables too high?
Nanobiotix's current Other Current Payables is €0.61 Mil. Overall, Nanobiotix has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Nanobiotix's Other Current Payables compare to VRTX and REGN?
Nanobiotix's Other Current Payables of €0.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Nanobiotix and its competitors. Nanobiotix's current Other Current Payables is €0.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanobiotix stock overvalued right now?
Nanobiotix (LTS:0QAV) has a current Other Current Payables of €0.61 Mil. The current Other Current Payables is €0.61 Mil. Nanobiotix's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Nanobiotix (LTS:0QAV), the current Other Current Payables is €0.61 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nanobiotix Business Description

Address 60 Rue de Wattignies, Paris, FRA, 75012
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
28GF Score

Get the complete analysis for LTS:0QAV

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€35.24
Price